Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
2
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Target Indication
Neovascular Age-Related Macular Degeneration
Clinical Trial
NCT06223958Last updated: 12/4/2025
No patent data available. Pre-approval drugs may not have Orange Book listings.
Axitinib Accord
Axitinib Accord is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine.
View on EMAInlyta
Inlyta is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine.
View on EMAOpen Angle Glaucoma and Ocular Hypertension
Cataract
Post Ocular Surgical Inflammation and Pain
Non-Proliferative Diabetic Retinopathy
Open Angle Glaucoma